Siemens Healthineers: Tariff Refunds Mask a Diagnostics Downdraft
Revenue guidance cut to 3.5-4% on persistent China/legacy headwinds, but €0.15 EPS lift from tariff refunds and a robust equipment book-to-bill keep earnings on track
SHL.DE · Earnings Call · 2026-07-31
A Tale of Two Diagnostics
Siemens Healthineers' Q3 FY2026 call could not have been more split-screen. On one hand, the tariff refund—a one-time windfall flowing through from IEEPA adjustments—boosted profitability and led management to raise EPS guidance by exactly €0.15 to €2.35-2.45. On the other hand, the company lowered revenue guidance from 4.5-5% to 3.5-4%, squarely on the back of a legacy platforms decline and structural rebasing in China's Diagnostics market. As CFO Jochen Schmitz put it:
The tariff refund supported a very high profitability this quarter. Excluding tariffs, we had a decent margin level despite low absolute conversion and year-over-year headwinds from FX and inflation.
The market rebasing in China is not new—management flagged it throughout the past year—but the extent of the decline is. In Q3, Diagnostics revenue fell more than expected, and the expected slowdown of the decline “has not materialized,” as CEO Bernd Montag admitted. The division now sees China at only ~10% of group revenue and expects mid-single-digit percentage declines to persist through Q4. This is a fundamental narrative shift: the previous assumption of a recovery in H2 is gone, replaced by a “new baseline” with no visible green shoots.
The Synergetic Core Carries the Weight
While Diagnostics stumbles, the core Imaging/Precision Therapy businesses deliver. Equipment book-to-bill hit 1.27, excluding value partnerships it was still a strong ~1.17, and photon counting CT continues to reshape the market. CEO Bernd Montag highlighted that photon-counting now accounts for ~30% of CT equipment orders and that CT market share in the U.S. has reached the level traditionally seen in MRI (roughly 50%). The new value partnerships with Cleveland Clinic and Vanderbilt Health—together several hundred million euros in equipment orders—underscore the “holistic partner” positioning. Yet even here, a temporary stumble is visible: Imaging growth was soft (2.3%) on tough comps and site-readiness delays, but management guided a clear acceleration to high-single-digit growth in Q4. This is the same story as Q1: the core is strong but lumpy.
Also noteworthy is the deconsolidation of Siemens Healthineers from Siemens AG—the final step in a decade-long legal separation. Management is “well advanced” with preparations and explicitly said no branding fee is expected. This removes a long-standing overhang on the stock and offers a clearer standalone story. Prior calls had only hinted at this; now it is a concrete plan with a timeline (earliest April 2027).
Inflation, Tariffs, and the 2027 Bridge
For the first time, management provided a 2027 EPS bridge. The baseline is €2.25 (2026 EPS ex-tariff refund). They expect double-digit EPS growth over the midterm, but now warn that additional supply-chain inflation—notably memory chips, tungsten, and logistics—will roughly offset the tariff mitigation ramp in 2027. “On the tungsten side, I think that is also a volatile topic. And we have seen it peaking to 6x, I would say, the prices, and they came down again to, I don't know, 2 to 3x the pricing.” — Jochen Schmitz, CFO · 2026-07-31 This marks a cautious tone: the mitigation measures are “back-end loaded,” and the bridge implies only mid-single-digit EPS growth next year, not double-digit.
What Changed and Why It Matters
The key change is the removal of a plausible recovery narrative in Diagnostics. Previous calls held out hope that China would stabilize and legacy dilution would fade—see, for example, the February 2026 call: “When we look at the trajectory at the plans we have and also at the relevance this China business meanwhile only have or has for Diagnostics, we still feel that the midterm guidance we have out there for Diagnostics is a valid one.” — Veronika Dubajova, Analyst · 2026-02-05 That midterm guidance now looks increasingly aspirational. The company is effectively admitting that Diagnostics will be a drag for the foreseeable future, and the profit engine is the synergetic core.
This matters because the stock has been a steady compounder on the strength of Imaging and Varian. The downgrade in revenue is offset by the tariff refund, which is a non-recurring boost. Investors must now discount a lower-quality revenue mix and a persistent margin drag from Diagnostics. The deconsolidation, while a positive catalyst, won't fundamentally change the operational reality.
Weaving it together, the company is riding a global wave of tariff refunds—as seen in the tariff refund theme in the market's top keywords for 20263—but the underlying structural challenges in Diagnostics are company-specific and not yet resolved. The smart move would be to separate or restructure Diagnostics, but management has not committed to that, only saying they will “verticalize” it further.
Ultimately, Siemens Healthineers remains a high-quality medtech franchise, but today's call exposes a two-speed company: a thriving core and a declining diagnostics division. The €0.15 EPS gift from tariffs is a one-time sugar rush; the hangover will hit in 2027 when inflation pressures bite and tariff comparisons normalize.
“The debate is also very much about how can we support them doing more with less, how to live in a world with staff shortage...” — Julien Dormois, Analyst · 2026-07-31 That productivity angle is the core thesis that keeps the growth engine alive, but it cannot mask the diagnostics drag forever.